Bard PowerPort Catheter

FDA Issues Multiple Class I Recalls for Arrow International Vascular Access Kits

Published Jul 12, 2026Updated Jul 12, 2026

By People's Justice

What happened

The FDA classified multiple Arrow International, LLC vascular access kits — including PICC, hemodialysis, and CVC kits — under Class I recalls after Lidocaine, Bupivacaine, and 0.9% sodium chloride from a supplier with documented quality issues were incorporated into the products. The FDA noted limited reports of drug ineffectiveness and warned that compromised sterility of a water-based injectable product could lead to serious adverse health consequences. These recalls were detected on June 30, 2026.

Event date: Jun 30, 2026

Source: api.fda.gov

Bard PowerPort Catheter case guide Check eligibility

Related news

Oct 3, 2026
Bard PowerPort Catheter
Judge Denies Bard's Bid to Dismiss Port Catheter Bellwether Case
The federal judge overseeing the Bard PowerPort multidistrict litigation in Arizona denied a motion for summary judgment filed by C.R. Bard Inc. and Becton Dickinson and Co., allowing a woman's design-defect claims to proceed to the third bellwether trial in the MDL, according to Mealey's and Bloomberg Law.
Source: mealeys.com
Sep 30, 2026
Bard PowerPort Catheter
FDA Issues Class I Recall for Bard Power-Trialysis Dialysis Catheter
The FDA logged a Class I recall for Bard Access Systems' Power-Trialysis Short-Term Straight Dialysis Catheter (REF 5605150). The agency's database describes this as a downstream recall tied to an earlier Class I recall, RES 98777.
Source: api.fda.gov
Sep 29, 2026
Bard PowerPort Catheter
FDA Lists Class I Recall for Bard Power-Trialysis Catheter
The FDA's enforcement database lists a Class I recall for the Bard Access Systems Power-Trialysis Short-Term Straight Dialysis Catheter (REF 5605150), identified as a downstream recall tied to an earlier recall event, RES 98777.
Source: api.fda.gov